Össur/Embla is prosthetics and bracing and one of the world's leading orthopedic suppliers.
Össur — rebranded as Embla following its 2024 corporate identity update — is the world's leading company in non-invasive orthopedics, with particular strength in advanced prosthetics, functional bracing, and rehabilitation solutions. The company's prosthetic limb portfolio — including the RHEO KNEE bionic prosthetic knee and the PROPRIO FOOT — represents the technology frontier in advanced prosthetics. Össur/Embla's bracing portfolio serves the post-surgical rehabilitation and injury prevention markets with products for knee, ankle, back, and upper extremity applications.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Acquisitions and divestitures
• Marketing tactics
• Financial results
• Strengths and weaknesses
• Strategic directions
Table of Contents
1. Executive Summary
2. Company Overview and Business Model
3. Strategic Directions
4. Financial Results
5. SWOT Analysis
6. Technological Know-How and Key Products
7. Acquisitions and Divestitures
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Össur/Embla — Key Financial Metrics 2023-2025
Table 2. Össur/Embla — Revenue by Segment 2023-2025
Table 3. Össur/Embla — Revenue by Geography 2023-2025
Table 4. Össur/Embla — SWOT Analysis
Table 5. Össur/Embla — Key Products and Platforms 2025
Table 6. Össur/Embla — M&A Activity 2020-2025
Table 7. Össur/Embla — Key Management 2025
Table 8. Össur/Embla — Strategic Priorities 2025-2030
